Integra LifeSciences Reports Q3 2026 Results Amid Cincinnati Facility Disruption
Integra LifeSciences reported third-quarter revenue of $411.2 million, representing a 2.5% organic increase despite a $7 million headwind caused by flooding at its Cincinnati facility. While Specialty Surgery saw strong growth driven by neurosurgery and international markets, the Tissue Reconstruction segment experienced a 2.2% organic decline due to competitive pressures in the urinary bladder matrix portfolio. The company issued updated full-year 2026 revenue guidance of $1.634 billion to $1.654 billion, reflecting an extended recovery timeline for the Cincinnati site, which is expected to cause a further $15 million to $20 million in lost revenue in Q4. Despite these operational challenges, Integra achieved record third-quarter operating cash flow of $96 million and completed a $2.1 billion debt refinancing on October 19, 2026.
Tickers: $IART
Topics: Adjusted EPS Debt Refinancing Facility Disruption Financial Guidance Revenue Growth
Read the full article at Motley Fool
Part of the story Integra LifeSciences Reduces Full-Year Revenue Guidance Due to Plant Flooding and Market Competition (3 articles)